Figure 4 from Facts and Hopes: CAR T-Cell Therapy and Immune Contexture in Non-Hodgkin Lymphoma
Year: 2025
Type: other
Abstract: Schematic representation of CAR T-cell structure and mechanism of action. Designed CAR receptors comprising a receptor domain, CD28 co-stimulatory domain, and CD3ζ activation domain bind to CD19 antigens on the surface of lymphoma cells. This binding event initiates T-cell activation, triggering the release of granzymes and cytokines. Preexisting immune cells, including T cells and myeloid cells, support CAR-T cells through the production granzymes, cytokines, and chemokines. This process induces the targeted death of B-cell lymphoma. CCL2, chemokine ligand 2; CCL5, chemokine ligand 5; CXCL9, C-X-C motif chemokine ligand 9; GNLY, granulysin; GZMA, granzyme A; GZMB, granzyme B; ScFv, single-chain variable fragment.
Language: English
Topic: CAR-T cell therapy research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4414185697
Cites:
Cited by:
Related to: